NCT00278161 · OUTCOME

Non-relapse Mortality

Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma · Source last updated 2018-11-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 5 years

What was measured

Number of participants who died for reasons related to protocol treatment.

Groups in this outcome

R-HiCy

Rituximab (R) and high-dose cyclophosphamide (HiCy) with pegfilgrastim support. Pegfilgrastim: 6 mg SQ 24-48 hours after last dose of cyclophosphamide. Rituximab: 375 mg/m\^2/day on Days 1, 4, 8, 11, 45, and 52. Cyclophosphamide: 50 mg/kg/day on Days 15, 16, 17, and 18.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
R-HiCy	81

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
R-HiCy	0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
0

denoms

counts
group Id
OG000
value
81
units
Participants

description

Number of participants who died for reasons related to protocol treatment.

groups

description
Rituximab (R) and high-dose cyclophosphamide (HiCy) with pegfilgrastim support. Pegfilgrastim: 6 mg SQ 24-48 hours after last dose of cyclophosphamide. Rituximab: 375 mg/m\^2/day on Days 1, 4, 8, 11, 45, and 52. Cyclophosphamide: 50 mg/kg/day on Days 15, 16, 17, and 18.
id
OG000
title
R-HiCy

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

5 years

title

Non-relapse Mortality

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice